Vext Science (VEXT) AI Stock Analysis

• Market Cap: C$45.80M
• Dividend Yield: N/A
• Average Volume (3M): 31.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 18.82%
• EPS Growth: -9328.57%
• Country: CA
• Employees: 173
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 180,306,050
• 10 Day Avg. Volume: 5,811
• 30 Day Avg. Volume: 31,348
• PEG Ratio: -0.09
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 7.62
• Enterprise Value/Market Cap: 1.38
• Enterprise Value/Revenue: 0.44
• Enterprise Value/Gross Profit: 6.38
• Enterprise Value/Ebitda: 2.86
• 1Y Price Target: C$0.51
• Price Target Upside: 181.48% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Vext Science's overall score reflects the robust operational performance and expansion efforts, particularly in Ohio, which are driving revenue growth and improving cash flow. However, the company's declining profitability, negative P/E ratio, and valuation concerns significantly weigh down the score. The positive technical indicators and strategic corporate events slightly bolster the overall perception of the stock.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science is a cannabis operator based in the United States, primarily engaged in the cultivation, production, and retailing of cannabis products. The company operates in the healthcare and retail sectors, offering a diverse range of cannabis-related products, including dried flower, edibles, and concentrates. Vext Science focuses on delivering high-quality cannabis products through its owned facilities and retail locations, catering to both medical and recreational cannabis markets.

How the Company Makes Money

Vext Science generates revenue through the cultivation and sale of cannabis products in states where cannabis is legal. The company's key revenue streams include wholesale distribution to dispensaries and direct sales through its own retail outlets. Vext Science benefits from vertical integration, owning and operating cultivation facilities, production sites, and retail dispensaries, which allows them to capture value at multiple points in the supply chain. Additionally, the company may engage in strategic partnerships or licensing deals to expand its product offerings and market reach, contributing to its overall earnings.

Vext Science Financial Statement Overview

Summary

Vext Science is experiencing revenue growth but struggles with declining profitability and negative net profit margins. The balance sheet shows moderate leverage, and while cash flow has improved, its sustainability remains a concern due to historical volatility.

Income Statement

Vext Science shows fluctuating financial performance with recent revenue growth of 8.8% in the TTM period. The gross profit margin decreased from the previous year, and the company is currently experiencing negative net profit and EBIT margins, indicating profitability challenges. Despite some revenue growth, the declining profitability metrics present significant concerns.

Balance Sheet

The balance sheet reveals moderate financial leverage with a debt-to-equity ratio of 0.52 in the TTM period, indicating manageable debt levels. However, the equity ratio has declined over time, reflecting increased liabilities. Return on equity is negative due to net losses, highlighting challenges in generating returns for shareholders.

Cash Flow

Vext Science has shown improvement in operating cash flow, with a positive free cash flow in the TTM period. The operating cash flow to net income ratio indicates strong cash generation relative to reported losses, suggesting efficient cash management. However, the historical volatility in free cash flow growth poses a risk to sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.14, and above the 200-day MA of 0.16, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 67.66 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	68 Neutral	$54.79M	4.04	20.78%	―	-15.44%	―
VEXT	65 Neutral	C$45.80M	―	-24.12%	―	18.82%	-9328.57%
ROMJ	56 Neutral	C$28.55M	―	-2.68%	―	29.78%	68.83%
CXXI	56 Neutral	C$33.00M	―	-12.58%	―	9.90%	-24.19%
LABS	54 Neutral	C$29.06M	―	-16.22%	―	16.24%	46.47%
Sector *	46 Neutral	C$201.68M	-3.28	-23.14%	1.87%	20.75%	-0.36%
GWAY	44 Neutral	C$32.99M	―	-18.73%	―	44.21%	21.93%

Vext Science Corporate Events

Vext Science Expands Ohio Footprint with New Fairfield Dispensary

Vext Science, Inc. has secured a provisional license for its sixth cannabis dispensary in Fairfield, Ohio, with operations expected to commence in the fourth quarter of 2025, subject to regulatory approvals. This strategic expansion highlights Vext’s disciplined approach to growth, leveraging high-traffic locations and limited competition to drive cash flow and shareholder value. The new Fairfield location, adjacent to Jungle Jim’s International Market, is expected to enhance visibility and consumer traffic, further solidifying Vext’s market position in Ohio as it approaches the state’s dispensary license cap of eight.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Expands Ohio Presence with Fifth Dispensary Opening

Vext Science, Inc. has opened its fifth cannabis dispensary in Portsmouth, Ohio, enhancing its retail footprint in the state. The new location, which includes a drive-thru, is part of Vext’s strategy to scale its operations and increase market presence in Ohio, a key growth area for the company. The Portsmouth dispensary is expected to be fully consolidated by late 2025, subject to regulatory approval. Vext’s vertically integrated model in Ohio positions it to drive margin expansion and free cash flow, supporting its long-term growth and shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science, Inc. Transitions to New Auditor Amid Growth

Vext Science, Inc. has announced a change of auditor from Reliant CPA to MNP LLP, effective June 4, 2025. The change was initiated by the former auditor due to the company’s growth exceeding its audit practice’s scope. The new auditor, MNP LLP, is expected to better meet Vext’s financial reporting needs due to its greater public company experience. The transition is not associated with any reservations or reportable events, and has been approved by the board.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Achieves Record Q1 Revenue and Expands Ohio Footprint

Vext Science reported a record Q1 performance with $11.6 million in revenue, a 38% increase from Q1 2024, driven by growth in Ohio. The company’s operating cash flow reached $3.1 million, matching its entire 2024 cash generation, highlighting the success of its retail strategy. Vext doubled its Ohio retail footprint by acquiring two dispensaries, enhancing its market presence. The company is focused on expanding in Ohio, reducing debt, and delivering sustainable returns for shareholders.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.60 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science to Release Q1 2025 Financial Results on May 21

Vext Science, Inc. announced it will release its Q1 2025 financial results on May 21, 2025, before the market opens. The company will also host a conference call and webcast to discuss these results, reflecting its continued focus on growth and stakeholder engagement in its core markets of Arizona and Ohio.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.